Funding

Galux

South Korea · Biotech · AI

Develops AI-driven protein design platform for de novo antibody and drug discovery

Visit galux.co.krFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series B$29MDAYLI Partners — Role not disclosedInterVest — Role not disclosedKorea Development Bank (KDB) — Role not disclosedKorea Investment & Securities — Role not disclosedMirae Asset Securities — Role not disclosedNCORE Ventures — Role not disclosedPathway Investment — Role not disclosedSL Investment — Role not disclosedSneakPeek Investments — Role not disclosedYuanta Investment — Role not disclosed

Investors

DAYLI PartnersSeries BInterVestSeries BKorea Development Bank (KDB)Series BKorea Investment & SecuritiesSeries BMirae Asset SecuritiesSeries BNCORE VenturesSeries BPathway InvestmentSeries BSL InvestmentSeries BSneakPeek InvestmentsSeries BYuanta InvestmentSeries B

Coverage

Feb 9, 2026Galux · Series B

Similar companies

Estuary BiotherapeuticsEstuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.$93M · Series A
GasLabGasLab is developing a generative music platform that links AI-created tracks to participating artists and rights holders so they can share in the revenue.~$1M · Pre-seed
HoloHolo helps small businesses plan marketing campaigns, create content and publish it across connected channels.€5M · Seed
Sourcesgalux.co.kr ↗